Ipsen telegraphed plans to acquire Epizyme and the FDA-approved Tazverik in June 2022, two years after the med’s clearance in the U.S. as both an epithelioid sarcoma and follicular lymphoma treatment.

Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.

After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through ...

The FDA will end a roughly nine-month hiatus of drug-related advisory committee meetings, with plans to convene its first session of 2026 to scrutinize a pair of oncology applications from AstraZen | ...

Tommy DeCarlo, who sang with the band Boston for nearly 20 years after posting a Myspace tribute to the band’s original singer, has died at 60. On Monday, DeCarlo’s children said he died ...

Brenna Huckaby and her snowboard have been showstoppers at the Milan Cortina Paralympic Games. There’s Huckaby in glitter and ...

The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medicatio ...

Read more about how occupational therapy interventions mitigate chemotherapy-induced cognitive impairment among women with breast cancer.

Order comes as Bayer proposes a settlement for thousands of Roundup lawsuits and all branches of government consider pesticide maker liability ...

-- Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. -- Transaction represents ...

The Missouri court handling the proposed class settlement gave preliminary approval, though some plaintiffs petitioned to ...

A new study reveals the dual use of a FAP molecule that inhibits fibrosis and facilitates drug delivery, offering insights ...